- Home
- GDYN vs TARS Comparison
GDYN vs TARS Comparison
Compare GDYN & TARS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GDYN
- TARS
- Stock Information
- Founded
- GDYN 2006
- TARS 2016
- Country
- GDYN United States
- TARS United States
- Employees
- GDYN N/A
- TARS N/A
- Industry
- GDYN Computer Software: Prepackaged Software
- TARS Medicinal Chemicals and Botanical Products
- Sector
- GDYN Technology
- TARS Health Care
- Exchange
- GDYN Nasdaq
- TARS Nasdaq
- Market Cap
- GDYN 1.8B
- TARS 2.1B
- IPO Year
- GDYN N/A
- TARS 2020
- Fundamental
- Price
- GDYN $20.80
- TARS $46.74
- Analyst Decision
- GDYN Strong Buy
- TARS Strong Buy
- Analyst Count
- GDYN 7
- TARS 5
- Target Price
- GDYN $18.14
- TARS $54.20
- AVG Volume (30 Days)
- GDYN 1.5M
- TARS 709.0K
- Earning Date
- GDYN 02-20-2025
- TARS 02-25-2025
- Dividend Yield
- GDYN N/A
- TARS N/A
- EPS Growth
- GDYN N/A
- TARS N/A
- EPS
- GDYN 0.03
- TARS N/A
- Revenue
- GDYN $328,358,000.00
- TARS $129,621,000.00
- Revenue This Year
- GDYN $12.94
- TARS $917.88
- Revenue Next Year
- GDYN $18.35
- TARS $78.70
- P/E Ratio
- GDYN $709.65
- TARS N/A
- Revenue Growth
- GDYN 4.10
- TARS 801.96
- 52 Week Low
- GDYN $9.07
- TARS $20.08
- 52 Week High
- GDYN $24.16
- TARS $57.14
- Technical
- Relative Strength Index (RSI)
- GDYN 52.62
- TARS 37.90
- Support Level
- GDYN $20.48
- TARS $43.61
- Resistance Level
- GDYN $21.30
- TARS $57.00
- Average True Range (ATR)
- GDYN 0.75
- TARS 2.72
- MACD
- GDYN -0.21
- TARS -1.16
- Stochastic Oscillator
- GDYN 30.86
- TARS 23.13
About GDYN Grid Dynamics Holdings Inc.
Grid Dynamics Holdings Inc provides enterprise-level digital transformation in the areas of search, analytics, and release automation to Fortune 1000 companies. The company delivers tailored solutions in several industry verticals like Tech, Media and Telecom, Retail, Finance and Consumer Packaged goods (CPG)/manufacturing. The company derives maximum revenue from Retails. Geographically company earns revenue from North America, Europe and other regions.
About TARS Tarsus Pharmaceuticals Inc.
Tarsus Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. It is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's candidate XDEMVY is a novel investigational eye drop to treat blepharitis caused by the infestation of Demodex mites, referred to as Demodex blepharitis.